Multidisciplinary Pain Centre, Department of Anaesthesiology, University of Munich, Munich, Germany.
BMC Musculoskelet Disord. 2010 Feb 11;11:32. doi: 10.1186/1471-2474-11-32.
Myofascial pain is a common dysfunction with a lifetime prevalence affecting up to 85% of the general population. Current guidelines for the management of myofascial pain are not available. In this study we investigated how physicians on the basis of prescription behaviour evaluate the effectiveness of treatment options in their management of myofascial pain.
We conducted a cross-sectional, nationwide survey with a standardized questionnaire among 332 physicians (79.8% male, 25.6% female, 47.5 +/- 9.6 years) experienced in treating patients with myofascial pain. Recruitment of physicians took place at three German meetings of pain therapists, rheumatologists and orthopaedists, respectively. Physicians estimated the prevalence of myofascial pain amongst patients in their practices, stated what treatments they used routinely and then rated the perceived treatment effectiveness on a six-point scale (with 1 being excellent). Data are expressed as mean +/- standard deviation.
The estimated overall prevalence of active myofascial trigger points is 46.1 +/- 27.4%. Frequently prescribed treatments are analgesics, mainly metamizol/paracetamol (91.6%), non-steroidal anti-inflammatory drugs/coxibs (87.0%) or weak opioids (81.8%), and physical therapies, mainly manual therapy (81.1%), TENS (72.9%) or acupuncture (60.2%). Overall effectiveness ratings for analgesics (2.9 +/- 0.7) and physical therapies were moderate (2.5 +/- 0.8). Effectiveness ratings of the various treatment options between specialities were widely variant. 54.3% of all physicians characterized the available treatment options as insufficient.
Myofascial pain was estimated a prevalent condition. Despite a variety of commonly prescribed treatments, the moderate effectiveness ratings and the frequent characterizations of the available treatments as insufficient suggest an urgent need for clinical research to establish evidence-based guidelines for the treatment of myofascial pain syndrome.
肌筋膜疼痛是一种常见的功能障碍,终生患病率高达 85%,影响到普通人群。目前尚无肌筋膜疼痛管理的指南。在这项研究中,我们调查了医生根据处方行为如何评估他们在肌筋膜疼痛管理中治疗选择的有效性。
我们对 332 名(79.8%为男性,25.6%为女性,47.5 +/- 9.6 岁)有治疗肌筋膜疼痛经验的医生进行了一项横断面、全国性的标准化问卷调查。招募医生是在德国疼痛治疗师、风湿病学家和骨科医生的三次会议上进行的。医生估计他们在实践中患者肌筋膜疼痛的患病率,陈述他们常规使用的治疗方法,然后用六点量表(1 为极好)评估治疗的感知效果。数据表示为平均值 +/- 标准差。
活跃的肌筋膜触发点的总体估计患病率为 46.1 +/- 27.4%。经常开的治疗药物是止痛药,主要是扑热息痛/对乙酰氨基酚(91.6%)、非甾体抗炎药/昔布(87.0%)或弱阿片类药物(81.8%),以及物理疗法,主要是手动疗法(81.1%)、TENS(72.9%)或针灸(60.2%)。止痛药(2.9 +/- 0.7)和物理疗法的总体疗效评价为中等(2.5 +/- 0.8)。不同专科之间各种治疗选择的疗效评价差异很大。所有医生中有 54.3%认为现有的治疗选择不足。
肌筋膜疼痛被估计为一种普遍存在的疾病。尽管有各种各样的常用治疗方法,但中度的疗效评价以及对现有治疗方法经常不足的描述表明,迫切需要开展临床研究,为肌筋膜疼痛综合征的治疗制定基于证据的指南。